230
Participants
Start Date
May 16, 2023
Primary Completion Date
November 7, 2026
Study Completion Date
April 10, 2029
Paclitaxel
80-100 mg/m\^2 IV infusion, administered on days 1, 8, and 15 of every 28-day cycle.
Irinotecan
180 mg/m\^2 IV infusion, administered on day 1 of every 14-day cycle.
Pembrolizumab
200 mg IV infusion, administered every Q3W up to 35 infusions.
MK-4830
800 mg IV infusion, administered Q3W up to 35 infusions.
Lenvatinib
20 mg oral administration every day.
Sacituzumab tirumotecan
4 mg/kg or 5 mg/kg IV infusion on Days 1, 15, and 29 of each 42-day cycle.
Antihistamine
Administered per product label.
H2 Receptor Antagonist
Administered per product label.
Acetaminophen (or equivalent)
Administered per product label.
Dexamethasone (or equivalent)
Administered per product label.
Steroid Mouthwash (dexamethasone or equivalent)
Administered per product label.
Supportive care measures
Participants are allowed to take supportive care measures for the management of adverse events associated with study intervention at the discretion of the investigator. Artificial tear drops or ointment may be given as a supportive care for Ocular Surface Toxicity.
RECRUITING
Taipei Veterans General Hospital ( Site 4005), Taipei
RECRUITING
Taichung Veterans General Hospital-Radiation Oncology ( Site 4008), Taichung
RECRUITING
National Cheng Kung University Hospital ( Site 4001), Tainan City
RECRUITING
Hôpitaux Universitaires de Genève (HUG) ( Site 4702), Geneva
RECRUITING
Kantonsspital Graubünden-Medizin ( Site 4700), Chur
RECRUITING
National Taiwan University Hospital ( Site 4000), Taipei
COMPLETED
Columbia University Irving Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical ( Site 4907), New York
RECRUITING
Chulalongkorn University ( Site 4104), Bangkok
RECRUITING
Faculty of Medicine Siriraj Hospital ( Site 4102), Bangkok
RECRUITING
Hematology-Oncology Associates of Central NY, P.C. ( Site 4925), East Syracuse
COMPLETED
Charité Campus Virchow-Klinikum-Klinik Hämatologie Onkologie Tumorimmunologie ( Site 4804), Berlin
RECRUITING
UPMC Hillman Cancer Center-UPMC ( Site 4904), Pittsburgh
RECRUITING
Ospedale San Raffaele-Oncologia Medica ( Site 3202), Milan
RECRUITING
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 3200), Milan
COMPLETED
Istituto Europeo di Oncologia IRCCS-Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative ( Site 3201), Milan
RECRUITING
Atatürk Üniversitesi-onkoloji ( Site 3416), Erzurum
RECRUITING
Chang Gung Medical Foundation-Linkou Branch ( Site 4006), Taoyuan District
RECRUITING
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 3403), Istanbul
RECRUITING
Istituto Oncologico Veneto IRCCS-Oncologia Medica 1 ( Site 3203), Padua
COMPLETED
I.E.U. Medical Point Hastanesi-Oncology ( Site 3406), Izmir
COMPLETED
Universitaetsklinikum Duesseldorf ( Site 4802), Düsseldorf
RECRUITING
"IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori-Oncologia Medica ( Site 3207)", Meldola
RECRUITING
Azienda Ospedaliero Universitaria Pisana ( Site 3206), Pisa
COMPLETED
Institut für Klinisch Onkologische Forschung-Klink für Onkologie und Hämatologie ( Site 4801), Frankfurt am Main
RECRUITING
Chang Gung Memorial Hospital at Kaohsiung ( Site 4003), Kaohsiung Niao Sung Dist
RECRUITING
University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 4927), Tucson
RECRUITING
Songklanagarind hospital ( Site 4105), Hat Yai
RECRUITING
UCLA Hematology/Oncology - Santa Monica ( Site 4905), Los Angeles
RECRUITING
Beijing Cancer hospital-Digestive Oncology ( Site 3500), Beijing
RECRUITING
National University Hospital ( Site 3800), Singapore
RECRUITING
Shanghai Chest Hospital-Esophageal surgery department ( Site 3513), Shanghai
RECRUITING
First Huai'an Hospital Affiliated to Nanjing Medical University ( Site 3506), Huai'an
RECRUITING
Anhui Provincial Hospital South District ( Site 3501), Hefei
RECRUITING
Zhejiang Cancer Hospital-Thoracic oncology ( Site 3511), Hangzhou
RECRUITING
China Medical University Hospital ( Site 4007), Taichung
RECRUITING
The First Affiliated Hospital of Xinxiang Medical University-Oncology ( Site 3510), Xinxiang
RECRUITING
Saitama Prefectural Cancer Center ( Site 3703), Kitaadachi-gun
RECRUITING
FALP-UIDO ( Site 4400), Santiago
RECRUITING
Centro de Oncología de Precisión-Oncology ( Site 4404), Santiago
COMPLETED
Clínica las Condes ( Site 4403), Santiago
RECRUITING
Clínica UC San Carlos de Apoquindo ( Site 4405), Santiago
RECRUITING
Liga Norte Riograndense Contra o Câncer ( Site 4303), Natal
RECRUITING
Hospital Nossa Senhora da Conceição ( Site 4301), Porto Alegre
RECRUITING
ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 4300), São Paulo
RECRUITING
Universitaetsklinikum Carl Gustav Carus Dresden-Medical Dept I - Medical Oncology ( Site 4806), Dresden
RECRUITING
Aichi Cancer Center ( Site 3702), Nagoya
RECRUITING
National Cancer Center Hospital East ( Site 3701), Kashiwa
RECRUITING
Shizuoka Cancer Center ( Site 3704), Nagaizumi-cho,Sunto-gun
RECRUITING
National Cancer Center Hospital ( Site 3700), Chuo-ku
RECRUITING
Oslo universitetssykehus, Radiumhospitalet ( Site 4501), Oslo
RECRUITING
Asan Medical Center-Department of Oncology ( Site 3901), Seoul
RECRUITING
Samsung Medical Center-Division of Hematology/Oncology ( Site 3900), Seoul
RECRUITING
Adana Medical Park Seyhan Hastanesi-Medikal Onkoloji ( Site 3417), Adana
COMPLETED
Hacettepe Universite Hastaneleri-oncology hospital ( Site 3402), Ankara
COMPLETED
Memorial Ankara Hastanesi-Medical Oncology ( Site 3408), Ankara
RECRUITING
Ankara Bilkent City Hospital-Medical Oncology ( Site 3405), Ankara
Merck Sharp & Dohme LLC
INDUSTRY